AZD4547 and FGFR Amplification in Advanced Solid Tumors

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of a phase I study of AZD4547 in patients with advanced tumors.

Clinical Pearls:

• AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), has demonstrated promise in patients who have FGFR amplification in their tumor.
• FGFR amplification is rare.
• Tumor biology is complex, so there may be other alterations that may predict if AZD4547 is working.
• Of 21 patients dosed with AZD4547, seven had high FGFR and three of these patients (squamous NSCLC, breast and bladder cancer) had target lesion shrinkage or prolonged (≥24 weeks) disease stabilization.
• Further work is needed to better understand FGFR signaling.

<<<

View more from the 2014 ASCO Annual Meeting